PAOG Confirms CBD Nutraceutical Development And Distribution Partners
February 02 2021 - 1:55PM
InvestorsHub Cannabis NewsWire
Sandusky, OH -- February 2, 2021 --
InvestorsHub NewsWire -- PAO Group, Inc. (USOTC:
PAOG) today confirmed its plans to develop and distribute
cannabis nutraceuticals with Alkame Holdings, Inc. (USOTC:
ALKM) and North American Cannabis Holdings, Inc. (USTOC:
USMJ) as partners.
PAOG recently engaged with the Puerto Rico Consortium for Clinical
Investigation (PRCCI) to assist PAOG with developing its
proprietary Cannabidiol (CBD) extract into a nutraceutical product
to provide care for those experiencing issues associated with
Chronic Obstructive Pulmonary Disorder
(COPD).
Last year,
PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
RespRx is a cannabis treatment under development for Chronic
Obstructive Pulmonary Disorder (COPD) derived from a patented
cannabis extraction method - U.S. Patent No. 9,199,960 entitled
"METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS
INCLUDING THE CANNABIS
PLANT."
PAOG plans to work with ALKM in the
packaging of its nutraceuticals.
PAOG also plans to work with USMJ, in
addition to other distribution channels, to distribute PAOG
nutraceuticals through USJM’s ecommerce site www.usjm.com.
The business relationship with ALKM and
USMJ was established through PAOG’s partnership with Puration, Inc.
(USOTC:
PURA). Last year PAOG acquired a cannabis cultivation business
from PURA.
Learn more about
PAOG at www.paogroupinc.com.
Forward-Looking
Statements: Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.
CONTACT
INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
North American Cannabis (CE) (USOTC:USMJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
North American Cannabis (CE) (USOTC:USMJ)
Historical Stock Chart
From Sep 2023 to Sep 2024